Perceptive Gets a Big Boost From Pfizer’s Array Deal

The healthcare and biotech specialist enjoyed hefty gains in many of its top holdings on Monday.

Stephen Taub June 18, 2019

(Michael Nagle/Bloomberg)

What a day for Joseph Edelman’s Perceptive Advisors.Pfizer’s announcement that it agreed to acquire Array Biopharma for $10.64 billion in cash not only sent the shares of the cancer drug developer soaring, it sharply lifted the stocks of many other biopharmaceutical companies, especially those trying

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Market Intelligence

Data & Analysis

Guest Contributors

II Networks

Insights

Research

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.01 build:2025-12-11 Login